Stage 1: History
A 56-year-old woman from New Delhi presents with progressively worsening gait instability over the past two months. Eight weeks prior to presentation, she noticed a gradual onset of ascending symmetric sensations of painful "pins and needles" starting in her feet. Two weeks prior to presentation, her paresthesias spread to her hands, accompanied by short-term memory impairment, difficulty concentrating, irritability, anorexia, and episodic palpitations. She reports an inability to feel her feet on the ground when walking, leading to frequent stumbling and needing to brace herself against walls for balance. She reports no headaches, focal muscle weakness, fever, or weight loss.
Medical History: Hypertension, hypothyroidism (treated with stable levothyroxine 150 mcg/day for over a decade), depression, and anxiety. Four weeks before presentation, her primary physician increased her levothyroxine dose in response to a newly elevated serum thyrotropin (TSH) level of 8.8 µIU/mL (normal range 0.3-4.2) with a free thyroxine (T4) level of 1.5 ng/dL (normal range 0.9-1.8).
Surgical History: 30 years ago, she was involved in a motor vehicle collision resulting in a splenectomy and post-traumatic arthritis of the left hip. 20 years ago, she underwent a left total hip arthroplasty (THA). 1 year ago, she experienced an atraumatic dislocation of her left hip prosthesis treated with closed reduction. 12 weeks ago, due to persistent hip instability and pain, she underwent revision left hip arthroplasty at an outside hospital (details of surgery unknown at presentation).
Medications: Amlodipine, Levothyroxine (recently escalated), Fluoxetine.
Personal History: Consumes ~3 glasses of wine daily for the past 20 years; 30 pack-year smoking history.
Hello, Chief Resident here.
Key Findings:
* Subacute ascending symmetric painful paresthesias, sensory ataxia, cognitive/neuropsychiatric symptoms, and palpitations starting 4 weeks after revision left THA.
* Elevated TSH despite normal free T4.
* History of chronic alcohol consumption.
Differential Diagnoses:
1. Arthroprosthetic Cobalt Toxicity (55%): Strong temporal link to revision THA. Unifies sensory-predominant polyneuropathy, cognitive/mood changes, thyroid dysregulation (elevated TSH), and potential cardiotoxicity (palpitations).
2. Vitamin B12 Deficiency / Subacute Combined Degeneration (25%): Fits sensory ataxia, symmetric paresthesias, and neuropsychiatric features; risk increased by chronic alcohol use.
3. Alcoholic Polyneuropathy / Thiamine (B1) Deficiency (15%): Alcohol abuse causes distal symmetric neuropathy, memory decline, and autonomic symptoms.
4. Paraneoplastic Neuropathy or Heavy Metal Toxicity (Non-Cobalt) (5%): Subacute presentation of sensorimotor neuropathy, though less specific to recent surgical history.
Recommended Prioritized Tests:
1. Serum and whole blood cobalt and chromium levels.
2. Serum Vitamin B12, methylmalonic acid (MMA), and folate levels.
3. Serum thiamine (Vitamin B1) level.
4. Electromyography (EMG) and Nerve Conduction Studies (NCS).
5. Transthoracic Echocardiogram (evaluating for cobalt-induced cardiomyopathy).
Hello Attending Consultant here
Top 3 DDx:
1. Arthroprosthetic cobaltism (metallosis from MoM revision THA)
2. Subacute combined degeneration (B12 deficiency)
3. Toxic-metabolic neuropathy (EtOH/thiamine)
Critique/Improvements:
Resident plan is solid on cobalt prioritization and temporal linkage but underweights implant details and over-relies on empiric echo. Misses urgent need for prosthesis interrogation.
5-7 Specific Points:
1. Obtain operative report/implant stickers ASAP—confirm MoM or modular neck.
2. Add serum/urine toxic metals panel (Pb, As, Hg) to exclude co-exposures.
3. Order anti-IF Ab, homocysteine with B12/MMA for completeness.
4. Defer echo unless troponin/BNP elevated or ECG abnormal; prioritize MRI neuroaxis.
5. Quantify EtOH via CDT/GGT; start empiric thiamine before glucose.
6. NCS/EMG: specify sensory-predominant axonal pattern expected in cobalt.
7. Hold levothyroxine escalation pending cobalt levels (thyroiditis mimic).
Hello, Expert Clinician here.
Best unifying diagnosis: Arthroprosthetic cobalt toxicity (systemic cobaltism/metallosis) after revision total hip arthroplasty, likely from metal-on-metal or modular-component wear. It explains the subacute painful sensory polyneuropathy with sensory ataxia, cognitive/behavioral changes, thyroid dysfunction, anorexia, and palpitations.
Key pivot: Symptoms began approximately four weeks after hip revision and involve multiple cobalt-sensitive systems. The elevated TSH with normal free T4 prompted levothyroxine escalation but may instead be an early toxic effect; the dose change does not explain the preceding neuropathy.
Top differentials:
- B12 or copper deficiency: Can cause sensory ataxia and cognitive symptoms; check B12, MMA, homocysteine, copper, CBC. Less able to explain the postoperative timing and palpitations.
- Alcohol-related neuropathy/thiamine deficiency: Painful distal neuropathy is plausible, but usually more chronic and does not explain thyroid abnormalities.
- CIDP/GBS-spectrum neuropathy: Ascending symptoms fit, but absent weakness/areflexia data and multisystem features argue against it.
- Other heavy metals, especially arsenic: Painful neuropathy fits, but no exposure clue.
Immediate move: Urgently obtain operative records/implant specifications, whole-blood cobalt and chromium levels, hip radiographs plus metal-artifact-reduction MRI/ultrasound, and orthopedic-toxicology consultation. Obtain ECG, troponin/BNP, and echocardiography if abnormal or symptomatic. If cobaltism is confirmed, definitive treatment is removal/revision of the offending components.
Pearl: Chelation alone is ineffective without source control.
Stage 2: Exam + Basic Labs
Physical Examination:
Vitals: Afebrile, BP 128/90 mmHg, HR 105 bpm (sinus tachycardia), RR 16 breaths/min, SpO2 98% on room air. BMI 24 kg/m².
Mental Status: Oriented to person, place, and time, but exhibits short-term memory impairment (unable to recall what she had eaten for dinner the night before).
Neurologic Exam: Normal cranial nerve exam. Motor strength 5/5 in all four limbs. Sensation to light touch is reduced distally in all four extremities (glove-and-stocking distribution). Decreased proprioception and vibratory sensation at the feet and ankles. Patellar deep-tendon reflexes normal (2+); ankle reflexes not assessed. Wide-based ataxic gait with marked difficulty performing tandem gait. Positive Romberg test.
Cardiovascular / Respiratory / Abdomen: Unremarkable except for sinus tachycardia.
Laboratory Investigations:
- Complete Blood Count: WBC 12,700/µL (81% neutrophils, 10% lymphocytes, 7% monocytes, 1% eosinophils, 1% basophils; WBC was 11,500/µL 7 weeks prior).
- Hemoglobin: 18.8 g/dL with MCV 86 fL. (Historical Hb levels: 12.5 g/dL 1 year ago, 17.8 g/dL 8 weeks ago, and 19.0 g/dL 1 week ago). Platelet count: 209,000/µL. Serum Ferritin: 355 ng/mL (normal 30-336).
- Metabolic Panel: Serum Potassium 2.4 mmol/L (Hypokalemia), Serum Magnesium 1.6 mg/dL (Hypomagnesemia), Blood Glucose 250 mg/dL, HbA1c 7.5%. Vitamin B12: 1100 pg/mL (normal 232-1245). Potassium and magnesium normalized after repletion.
- LFTs, Serum Albumin, Bilirubin, Alkaline Phosphatase, CRP, ESR, and INR: All normal.
- Initial Diagnostic Imaging & Workup: ECG shows sinus tachycardia. Chest Radiography and Non-contrast Head CT: Normal. Echocardiogram: Normal biventricular systolic and diastolic function, no valvular or wall-motion abnormalities.
Hello, Chief Resident here.
Key Updated Findings:
* Severe secondary polycythemia (Hb 18.8 g/dL, acute rise post-THA).
* Sensory ataxia, impaired vibration/proprioception, and short-term memory impairment.
* Normal B12 (1100 pg/mL) excludes SCD/B12 deficiency. Newly recognized hyperglycemia (HbA1c 7.5%).
Differential Diagnoses:
1. Arthroprosthetic Cobalt Toxicity / Cobaltism (80%): Unifies post-THA subacute sensory polyneuropathy, cognitive decline, TSH dysregulation, and severe polycythemia (cobalt activates HIF-1α, driving EPO gene transcription).
2. Polycythemia Vera (PV) with Diabetic Neuropathy (10%): Explains erythrocytosis and new-onset diabetes, but does not fit the post-revision timing or rapid multisystem decline.
3. Paraneoplastic Neuropathy / EPO-Secreting Tumor (5%): E.g., renal cell carcinoma causing secondary polycythemia and neuropathy; less linked to surgical timing.
4. Alcoholic Polyneuropathy / Toxic Encephalopathy (5%): Contributes to chronic risk, but cannot account for marked polycythemia.
Prioritized Next Steps:
1. Whole blood and serum cobalt and chromium levels.
2. Left hip radiographs and Metal-Artifact Reduction Sequence (MARS) MRI to evaluate implant failure/pseudotumor.
3. Serum Erythropoietin (EPO) and JAK2 V617F mutation testing.
4. Urgent Orthopedic Surgery and Medical Toxicology consults for hardware revision and source control.
Hello Attending Consultant here
Top 3 DDx:
1. Arthroprosthetic cobaltism (HIF-1α–driven polycythemia + neuropathy)
2. JAK2+ polycythemia vera + concurrent toxic neuropathy
3. Paraneoplastic (EPO-secreting tumor) with sensory neuronopathy
Critique/Improvements:
Strong pivot to polycythemia as cobalt biomarker; correctly discards B12. Overweights PV prematurely and under-specifies implant interrogation urgency. Echo already normal—shift focus.
5-7 Specific Points:
1. STAT whole-blood Co/Cr (not serum alone); expect Co >100 µg/L.
2. Immediate retrieval of revision operative note/implant lot for MoM/modular taper confirmation.
3. Add serum EPO, JAK2, and abdominal US/CT to exclude renal mass.
4. MARS-MRI + XR of left hip for ALVAL/pseudotumor now.
5. Repeat TSH/free T4; hold further levothyroxine titration.
6. NCS/EMG + thiamine/copper levels for residual toxic-metabolic overlap.
7. Ortho-tox consult same-day; source control supersedes chelation.
Hello, Expert Clinician here.
Best unifying diagnosis: Systemic arthroprosthetic cobalt toxicity (cobaltism) from the recently revised hip prosthesis. It unifies sensory-predominant polyneuropathy with proprioceptive ataxia, cognitive changes, sinus tachycardia, thyroid dysfunction, hyperglycemia, and striking erythrocytosis. Cobalt stabilizes hypoxia-inducible factors, increasing erythropoietin despite normal oxygenation.
Key pivot: The rapidly acquired erythrocytosis (Hb 12.5→18–19 g/dL) accompanying multisystem symptoms beginning four weeks after revision THA strongly supports cobalt exposure rather than isolated nutritional, diabetic, or alcohol-related neuropathy.
Differentials:
- Polycythemia vera: Must exclude with EPO and JAK2 testing, but normal platelets and postoperative multisystem timing are less typical.
- EPO-driven secondary erythrocytosis from smoking, hypoxia, or renal tumor: possible, although normal saturation and rapid neurologic syndrome argue against it.
- Alcohol/thiamine or copper deficiency: Could contribute to neuropathy; does not explain erythrocytosis. Normal B12 makes B12 deficiency unlikely.
- Diabetic neuropathy: HbA1c 7.5% is unlikely to cause this rapid severe sensory ataxia.
Immediate move: Obtain urgent whole-blood cobalt and chromium levels, revision operative records/implant specifications, hip radiographs and MARS-MRI, with same-day orthopedics/toxicology consultation. Also send EPO/JAK2.
Teaching pearl: In cobaltism, definitive therapy is removal of the metal source; chelation cannot substitute for revision.
Stage 3: Advanced Workup & Prosthetic History
Serum Protein Electrophoresis (SPEP) and Serum Free Light-Chain Assay: Normal.
Infectious & Autoimmune Serology: ANA, anti-SSA (Ro), anti-SSB (La), RPR, HIV 1/2, HBsAg, anti-HCV, Lyme serology, and EBV PCR: All Negative. Serum thiamine and copper levels were not initially drawn.
Imaging & Revision Surgery Records Retrieval:
- Pelvic Radiograph: Left hip prosthesis is in proper alignment with no fracture or dislocation. However, prominent amorphous, cloudlike, radiopaque periarticular soft-tissue opacities are observed surrounding the left hip prosthesis (indicative of a large seroma with dispersed radiopaque metallosis deposits).
- Surgical Records from 12 Weeks Prior Revision:
- Original prosthesis implanted 20 years ago consisted of a titanium femoral stem, titanium acetabular shell, ceramic liner, and ceramic femoral head.
- Findings at revision 12 weeks ago: The ceramic femoral head had eroded through the ceramic liner and was articulating directly against the titanium acetabular shell.
- Procedure done at outside hospital: Extensive debridement of destroyed ceramic debris was performed. The eroded ceramic liner was replaced with a Polyethylene liner, and the ceramic femoral head was replaced with a metallic Cobalt-Chromium (CoCr) alloy femoral head. The titanium acetabular shell and stem were retained.
Hello, Chief Resident here.
Key Updated Findings:
* Pelvic X-ray confirms periarticular metallosis ("cloudlike radiopaque opacities").
* Surgical history reveals a classic mechanism for catastrophic wear: placing a CoCr metal head following ceramic erosion. Residual ceramic debris caused rapid third-body abrasive destruction of the CoCr head, driving massive cobalt release.
* Autoimmune and infectious panels are negative.
Differential Diagnoses:
1. Arthroprosthetic Cobaltism / Systemic Cobalt Toxicity (95%): Unifies the surgical mechanism, severe polycythemia (cobalt-driven EPO surge), subacute sensory-predominant polyneuropathy, sensory ataxia, cognitive changes, thyroid dysregulation, and tachycardia.
2. Multifactorial (Alcohol/Diabetic) Neuropathy with Incidental Metallosis (3%): Pre-existing risks contribute, but cannot explain the post-revision timing or secondary erythrocytosis.
3. Polycythemia Vera with Coincidental Hip Metallosis (2%): Unlikely given the rapid post-operative onset and classic metallosis history.
Prioritized Next Steps:
1. STAT Whole-Blood Cobalt and Chromium Levels (expect severely elevated cobalt, often >100–300 µg/L).
2. Left Hip MARS-MRI to evaluate soft-tissue destruction and pseudotumor burden.
3. Urgent Orthopedic Surgery Consult for revision/explantation of CoCr components and extensive synovectomy.
4. Toxicology Consult for perioperative management and consideration of chelation bridge.
5. Serum EPO and JAK2 V617F Mutation Testing to formally exclude polycythemia vera.
Hello Attending Consultant here
Top 3 DDx:
1. Arthroprosthetic cobaltism (third-body wear: CoCr head on ceramic debris)
2. Concurrent EtOH/thiamine neuropathy + metallosis
3. Local ALVAL/pseudotumor without full systemic cobaltism
Critique/Improvements:
Excellent mechanism capture and prioritization of source control. Slightly under-emphasizes immediate labs and residual toxic-metabolic workup; JAK2 now low-yield given radiographic metallosis.
5-7 Specific Points:
1. STAT whole-blood Co/Cr (target Co >>100 µg/L confirmatory).
2. MARS-MRI + US for pseudotumor volume/pre-op planning.
3. Same-day ortho revision: explant CoCr head, synovectomy, ceramic/poly exchange.
4. Draw thiamine/copper now; empiric thiamine repletion.
5. Serial ECG/troponin; hold chelation pending explant.
6. EPO only if Co normal; drop JAK2.
7. Post-explant Co monitoring q2wk until <10 µg/L.
Hello, Expert Clinician here.
Best unifying diagnosis: Systemic arthroprosthetic cobaltism from catastrophic third-body wear of the cobalt-chromium femoral head. Residual ceramic particles from the failed original bearing likely abraded the newly implanted CoCr head; taper corrosion may contribute. Radiographic periarticular metallosis corroborates ongoing metal release. This explains the painful sensory polyneuropathy, proprioceptive ataxia, cognitive changes, thyroid disturbance, tachycardia, hyperglycemia, and cobalt-mediated erythrocytosis via hypoxia-inducible-factor/EPO signaling.
Key pivot: Retrieval of the revision details—implanting a CoCr head after ceramic bearing destruction—plus visible metallosis converts cobalt toxicity from suspicion to the overwhelmingly likely diagnosis.
Differentials:
- Alcohol/thiamine or copper deficiency: May compound neuropathy but cannot explain the abrupt postoperative multisystem syndrome and erythrocytosis.
- Polycythemia vera/EPO-producing disease: Consider if erythrocytosis persists after cobalt removal or EPO/JAK2 findings are discordant.
- Diabetic neuropathy: HbA1c 7.5% cannot explain this rapid severe sensory ataxia.
- Local metallosis without systemic toxicity: Incompatible with the broad systemic manifestations.
Immediate move: Draw whole-blood cobalt and chromium urgently, then obtain same-day revision-arthroplasty and toxicology consultation for prompt removal of the CoCr source, extensive debridement/synovectomy, and appropriate nonmetal bearing reconstruction.
Teaching pearl: After ceramic bearing failure, residual ceramic debris can rapidly destroy a replacement metal head; source control—not chelation—is definitive.
Stage 4: Toxicological Evaluation & Revision Surgery
Pathophysiologic Mechanism:
Despite removal of macroscopic ceramic fragments during the prior revision, residual microscopic ceramic particles remained lodged in the soft tissues and synovium. Continuous friction of these hard, abrasive third-body particles against the newly implanted Cobalt-Chromium femoral head resulted in accelerated mechanical grinding, severe metallosis, and massive release of toxic cobalt ions into the bloodstream.
Heavy Metal Testing & Re-Revision Surgery:
- Heavy Metal Levels (Pre-operative samples, reported on HD 6):
- Serum Cobalt: 592 ng/mL (normal < 10 ng/mL) — Severely elevated (~60 times upper limit of normal).
- Serum Chromium: 62.4 ng/mL (normal < 0.2 ng/mL) — Severely elevated.
- Hospital Day 3 Intervention: The patient underwent emergency re-revision left hip arthroplasty with extensive soft-tissue debridement. Intraoperative findings confirmed extensive gray fluid collection and diffuse silver-gray discoloration of gluteus maximus, gluteus medius, and vastus lateralis with non-contractile tissue necrosis due to cobalt metallosis.
- Component Replacement: The Cobalt-Chromium femoral head was removed and replaced with a ceramic femoral head, along with installation of a new polyethylene liner.
- Chelation Therapy: Initiated on HD 3 with IV N-acetylcysteine and Calcium EDTA, followed by oral Succimer (2,3-dimercaptosuccinic acid 650 mg q8h) and N-acetylcysteine (1800 mg twice daily).
Hello, Chief Resident here.
Key Updated Findings:
* Confirmed Diagnosis: Extreme systemic cobaltism with serum Cobalt at 592 ng/mL (60x ULN) and Chromium at 62.4 ng/mL.
* Intraoperative Confirmation: Extensive pseudotumor, metallosis, and gluteal tissue necrosis secondary to third-body abrasive wear.
* Definitive Source Control: Re-revision to a ceramic femoral head/polyethylene liner completed on HD 3 alongside chelation therapy.
Differential Diagnoses:
1. Arthroprosthetic Cobaltism / Systemic Cobalt Toxicity (98%): Confirmed cause of multisystem failure—explaining the erythrocytosis (HIF-1α/EPO activation), sensory-predominant polyneuropathy, sensory ataxia, cognitive changes, thyroid dysfunction, and tachycardia.
2. Concomitant Alcohol/Diabetic Neuropathy (2%): Prior alcohol use and new-onset diabetes (HbA1c 7.5%) may offer a minor baseline sensory contribution, but do not explain the acute multisystem surge.
Recommended Next Steps:
1. Serial Metal Levels: Monitor whole-blood cobalt and chromium weekly to track clearance post-explantation and chelation.
2. Hematologic & Endocrine Follow-up: Monitor CBC for normalization of hemoglobin/hematocrit as cobalt-driven EPO stimulation wanes; re-check TSH and HbA1c.
3. Cardiac Surveillance: Repeat ECG and troponin; re-evaluate cardiac function prior to discharge.
4. Neurological Rehabilitation: Targeted physical therapy for sensory gait ataxia.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed arthroprosthetic cobaltism (third-body CoCr abrasion)
2. Residual EtOH/thiamine neuropathy overlay
3. Post-metallosis ALVAL with incomplete source clearance
Critique/Improvements:
Plan correctly prioritizes serial levels and rehab post-source control. Under-specifies chelation duration/toxicity monitoring and omits formal neurophysiologic baseline; cardiac surveillance redundant given prior normal echo.
5-7 Specific Points:
1. Switch to whole-blood Co/Cr q48–72h initially (serum underestimates).
2. Limit EDTA/succimer to 5 days; monitor renal function/Zn depletion.
3. Baseline NCS/EMG now for objective recovery tracking.
4. Empiric thiamine/copper repletion; redraw levels.
5. Hold further chelation if Co falls <100 ng/mL post-explant.
6. PT/OT with fall precautions; expect slow sensory recovery (months).
7. Outpatient ortho-tox follow-up with Co target <10 ng/mL.
Hello, Expert Clinician here.
Unifying diagnosis: Confirmed systemic arthroprosthetic cobaltism with chromium co-exposure, caused by third-body abrasion of the CoCr femoral head by retained ceramic particles. This produced severe local metallosis/necrosis and systemic sensory polyneuropathy with ataxia, cognitive dysfunction, thyroid disturbance, tachycardia, hyperglycemia, and likely HIF-mediated erythrocytosis.
Key pivot: Cobalt 592 ng/mL and chromium 62.4 ng/mL, together with diffuse intraoperative silver-gray necrosis, establish causality. Removal of the CoCr head is definitive source control.
Residual differentials:
- Alcohol/thiamine-related neuropathy: May delay recovery; does not explain the acute postoperative multisystem syndrome.
- Diabetic neuropathy: Possible contributor, but HbA1c 7.5% is insufficient for this rapid severe ataxia.
- Copper deficiency or alternative neurologic disease: Reconsider only if neurologic deficits fail to improve despite falling metal levels.
- Polycythemia vera: Unlikely; pursue JAK2/EPO only if erythrocytosis persists after detoxification.
Next move: Trend preferably whole-blood cobalt/chromium, CBC, renal/hepatic function, electrolytes, urinalysis, ECG, and thyroid indices. Chelation should be toxicology-directed with monitoring for EDTA/succimer toxicity and trace-element depletion. Obtain baseline EMG/NCS and begin intensive PT/OT with fall precautions.
Teaching pearl: Metal levels may transiently rebound from tissue redistribution; clinical improvement and sustained post-explant decline matter more than a single value.
Stage 5: Final Results & Outcome
Diagnosis:
Systemic Cobalt Toxicity (presenting as Cobalt-Induced Sensory Polyneuropathy, Encephalopathy, Secondary Polycythemia, Reversible Hyperglycemia, Escalated Hypothyroidism, Tachycardia, and Local Metallosis) secondary to third-body abrasive wear of a Cobalt-Chromium femoral head following revision hip arthroplasty.
Post-Treatment Clinical Course & Long-Term Follow-up:
- In-Hospital Recovery: Following removal of the cobalt source and soft-tissue debridement, serum hemoglobin dropped from 18.8 g/dL to 14.4 g/dL and remained stable throughout hospitalization, confirming resolution of cobalt-induced erythrocytosis.
- 6-Month Post-Discharge: Encephalopathy and gait ataxia completely resolved. HbA1c normalized to 5.5% (metformin discontinued), TSH normalized to 1.12 µIU/mL, allowing levothyroxine reduction back to her baseline dose of 150 mcg/day. Serum cobalt levels dropped to < 10 ng/mL.
- Otologic & Neuropathic Sequelae: Patient developed persistent tinnitus and left-sided high-frequency sensorineural hearing loss (cobalt-mediated ototoxicity to cochlear hair cells). Paresthesias partially improved with gabapentin.
- 1-Year Follow-up: Neuropathic pain significantly decreased, gait remained normal, tinnitus frequency reduced, and serum cobalt levels remained undetectable.
Hello, Chief Resident here.
Key Final Findings:
* Definitive Diagnosis: Systemic Arthroprosthetic Cobaltism secondary to catastrophic third-body wear of a CoCr femoral head against retained ceramic particles.
* Multisystem Resolution: Surgical explantation and chelation led to complete recovery of encephalopathy, sensory ataxia, cobalt-induced polycythemia (Hb 18.8 → 14.4 g/dL), hyperglycemia (HbA1c 7.5% → 5.5%), and thyroid dysregulation. Cobalt levels normalized (<10 ng/mL).
* Permanent Sequelae: Irreversible cochlear hair cell toxicity resulting in left-sided high-frequency sensorineural hearing loss and tinnitus, with partial sensory neuropathy improvement on gabapentin.
Final Diagnostic Probabilities:
1. Systemic Arthroprosthetic Cobalt Toxicity (100%): Confirmed by severe cobaltemia (592 ng/mL), intraoperative metallosis/necrosis, and rapid multisystem resolution post-explantation.
2. Polycythemia Vera / B12 Deficiency / EtOH Neuropathy (0%): Ruled out by full resolution following source control.
Key Takeaway:
Placing a metal head into a joint space containing retained ceramic debris risks rapid third-body abrasive destruction. In patients with revision THA presenting with new subacute neuropathy, ataxia, and unexplained secondary erythrocytosis, cobalt toxicity must be recognized immediately—definitive treatment requires surgical component removal, not chelation alone.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed arthroprosthetic cobaltism (third-body CoCr abrasion)
2. Residual cobalt ototoxicity/neuropathy
3. Concurrent EtOH-related sensory overlay (now excluded)
Critique/Improvements:
Resident summary accurately captures resolution kinetics and sequelae but under-emphasizes long-term surveillance for delayed cardiomyopathy or residual metallosis and omits formal audiometric/neurophysiologic endpoints.
5-7 Specific Points:
1. Annual whole-blood Co/Cr + ECG/echo for 2–3 yrs (late cardiomyopathy risk).
2. Formal audiometry + ENT for tinnitus/SNHL progression.
3. Serial NCS/EMG at 6/12 mo to quantify axonal recovery.
4. Avoid future MoM/CoCr implants; document ceramic-on-poly preference.
5. Counsel on fall risk until proprioception fully stabilizes.
6. Discontinue gabapentin trial if paresthesias plateau.
7. Ortho-tox clinic f/u q6 mo until Co undetectable ×2.
Hello, Expert Clinician here.
Final unifying diagnosis: Confirmed systemic arthroprosthetic cobalt toxicity with chromium co-exposure, caused by retained ceramic particles producing third-body abrasive wear of the revised cobalt-chromium femoral head. Manifestations included sensory polyneuropathy/ataxia, encephalopathy, HIF-mediated secondary erythrocytosis, reversible hyperglycemia and thyroid dysfunction, tachycardia, local metallosis, and delayed cochlear toxicity.
Key pivot: Severe cobaltemia (592 ng/mL), radiographic and operative metallosis, and rapid multisystem improvement after CoCr-head removal establish causality. Normalization of hemoglobin, HbA1c, TSH, gait, cognition, and cobalt levels is a strong dechallenge response.
Residual differentials: Alcohol-related, diabetic, or nutritional neuropathy became unlikely because metabolic abnormalities and gait dysfunction resolved after source control. Persistent paresthesias reflect residual cobalt-associated axonal injury. Unilateral high-frequency sensorineural hearing loss and tinnitus are compatible with cobalt ototoxicity.
Most important next move: Continue orthopedic surveillance and periodic whole-blood cobalt/chromium testing until repeatedly undetectable; obtain serial audiometry/ENT follow-up and symptom-directed neuropathy care. Reassess neurologically or with EMG/NCS if improvement plateaus or reverses.
Teaching pearl: After ceramic bearing failure, replacing the head with CoCr is hazardous because microscopic ceramic debris can rapidly abrade metal; definitive treatment of cobaltism is prompt source removal, while neurologic and auditory recovery may lag or remain incomplete.